GlaxoSmithKline (GSK) Earns Buy Rating from Jefferies Financial Group

Jefferies Financial Group reissued their buy rating on shares of GlaxoSmithKline (LON:GSK) in a report released on Friday. The firm currently has a GBX 1,580 ($20.65) price objective on the stock.

Other equities analysts also recently issued research reports about the company. UBS Group set a GBX 1,600 ($20.91) price objective on GlaxoSmithKline and gave the company a buy rating in a research note on Thursday, June 14th. Credit Suisse Group upped their price objective on GlaxoSmithKline from GBX 1,450 ($18.95) to GBX 1,600 ($20.91) and gave the company a neutral rating in a research note on Thursday, July 26th. Shore Capital reiterated a buy rating on shares of GlaxoSmithKline in a research note on Tuesday, August 7th. Berenberg Bank reiterated a buy rating and issued a GBX 1,790 ($23.39) price objective on shares of GlaxoSmithKline in a research note on Thursday, August 23rd. Finally, Deutsche Bank upped their price objective on GlaxoSmithKline from GBX 1,420 ($18.55) to GBX 1,525 ($19.93) and gave the company a hold rating in a research note on Tuesday, July 3rd. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of GBX 1,533.55 ($20.04).

GlaxoSmithKline stock traded down GBX 22.20 ($0.29) during trading on Friday, hitting GBX 1,429.40 ($18.68). The stock had a trading volume of 12,405,381 shares, compared to its average volume of 9,120,000. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($16.14) and a 1 year high of GBX 1,724.50 ($22.53).

The firm also recently announced a dividend, which was paid on Thursday, October 11th. Shareholders of record on Thursday, August 9th were issued a dividend of GBX 19 ($0.25) per share. The ex-dividend date was Thursday, August 9th. This represents a yield of 1.23%.

In other GlaxoSmithKline news, insider Philip R. Hampton bought 2,810 shares of the stock in a transaction on Wednesday, July 25th. The shares were acquired at an average price of GBX 1,557 ($20.34) per share, with a total value of £43,751.70 ($57,169.35). Also, insider David Redfern sold 1,925 shares of the business’s stock in a transaction on Tuesday, July 31st. The shares were sold at an average price of GBX 1,575 ($20.58), for a total transaction of £30,318.75 ($39,616.82). Insiders have acquired a total of 2,835 shares of company stock worth $4,413,165 in the last three months.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Story: Understanding each part of a balance sheet

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply